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Precision medicine is an emerging paradigm that aims at maxi-
mizing the benefits and minimizing the adverse effects of drugs.
Realistic mechanisticmodels are needed to understand and limit
heterogeneity in drug responses.While pharmacokineticmodels
describe in detail a drug’s absorption and metabolism, they
generally do not account for individual variations in response to
environmental influences, in addition to genetic variation. For
instance, the human gut microbiota metabolizes drugs and is
modulated by diet, and it exhibits significant variation among in-
dividuals. However, the influence of the gut microbiota on drug
failure or drug side effects is under-researched. Here, we review
recent advances in computational modeling approaches that
could contribute to a better, mechanism-based understanding of
drug–microbiota–diet interactions and their contribution to indi-
vidual drug responses. By integrating systems biology and
quantitative systems pharmacology with microbiology and
nutrition, the conceptually and technologically demand for novel
approaches could be met to enable the study of individual vari-
ability, thereby providing breakthrough support for progress in
precision medicine.
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The effect of drug treatment varies significantly among
individuals, and genetic differences alone are insuffi-
cient to explain the observed inter-individual differ-
ences in drug response [1]. Human gut microbeswww.sciencedirect.commetabolize many drugs [2]; however, their contribution
to an individual’s drug response and safety is poorly
understood. Diet also modulates the microbiota
composition and biochemical functions and alters drug
bioavailability. Recent technological advances have led
to a greater understanding of the diversity and abun-
dance of gut microbial species. Consequently, research
focus is shifting toward exploring the effects of a per-
son’s microbiota on metabolism and drug metabolism.
Accordingly, constraint-based computational models
have been applied to investigate how the gut microbiota
can modulate the human metabolic phenotype [3]. In
parallel, pharmacokinetic models are used to predict
drug responses at the whole-body level [4].
Despite these advances, computational modeling efforts
have yet not considered the joint effects of human gut
microbiota metabolism, drug metabolism and diet.
Consequently, neither the pharmaceutical industry nor
academic researchers can properly exploit the increasing
knowledge on the human gut microbiota as well as
microbiota- and diet-related interpersonal variability for
drug development and clinical trial design. The appli-
cation of statistical methods to genomic or clinical data
in pharmacogenomics has been of limited use for patient
and therapeutic stratification [5] and does not provide a
mechanistic system-level understanding of the targeted
biological systems. Another limitation of pharmacoge-
nomics is its failure to integrate exogenous factors that
alter drug bioavailability, such as the human gut micro-
biota or diet [6].
Human and microbial drug metabolism
Individual drug response. Variations in individual treat-
ment responses pose a major challenge to health pro-
fessionals and patients as well as to drug development
and clinical trial design [7]. Front-line physicians must
therefore adapt a pragmatic or empirical prescription
decision tree until an effective therapy for each patient is
identified. Furthermore, the adverse drug reactions that
may ensue are ranked among the top 10 causes of
morbidity and mortality in the developed world [8].
Certain adverse effects are related to the production of
toxic drug metabolites [9], and both the duration and
extent of pharmacological action are related to the rate of
drug metabolism [10]. Pharmacogenomic studies have
greatly improved our understanding of individual varia-
tions in drug metabolism caused by genetic individuality
[11]. However, these studies cannot explain the largeCurrent Opinion in Systems Biology 2017, 4:43–52
44 Pharmacology and drug discovery (2017)observed individual variability in drug response as they
only focus on the genetic variability of drug-metabolism
related genes. Consequently, variation in a person’s
physiology, such as gender, ethnicity, body mass index,
should be considered. Moreover, environmental factors,
such as diet, gut microbiota composition, exercise, and
stress, can modulate a person’s metabolic phenotype and
drug metabolism. As these factors can significantly alter
drug efficacy and safety profiles [12], they must be
accounted for in drug development and treatment.
Gut microbial drug metabolism. The human gut micro-
biota is a metabolically active community of 10e100
trillion commensal, pathogenic, and symbiotic organisms
composed of 500e1000 species and including two to four
million different genes [13,14]. The gut microbiota
contributes to the essential functions of the human host,
such as food digestion, essential amino acids and vitamin
synthesis, pathogen protection, and host immune system
maturation [15]. The gut microbiota has also emerged as
a significant factor influencing drug response [2]. Gut
microbes affect drug efficiency both directly and indi-
rectly. In turn, exposure to antibiotics and host-targeted
drugs induced changes in gutmicrobiota gene expression
across several phyla [16]. This xenobiotic modulation of
microbial gene expression varies between human in-
dividuals suggesting a gut microbiota-dependent
personalized drug response [16]. At least 30 host-
targeted drugs are directly affected by gut microbial ac-
tivity [17,18] (Figure 1), yet mechanistic insight in the
effects on drug efficiency and safety is often lacking [19].
Direct microbial effects on drugs include chemically
modifying drug structures, binding to drugs, and
degrading drugs [17,20]. The gut microbiome encodes
enzymes that perform drug transformations, including
reduction, acetylation, deacetylation, and demethyla-
tion [17]. In certain cases, these transformations result
in the desired conversion of a prodrug to an active drug.
For example, the prodrug sulfasalazine, a treatment for
inflammatory bowel disease, is cleaved into the active
drug 5-aminosalicylic acid by intestinal microbial azor-
eductases [17]. However, in other cases, the drug is
inactivated or converted into a more toxic form
(Figure 1). For example, the cardiac drug digoxin is
inactivated by the cardiac glycoside reductase of Egger-
thella lenta [21]. This undesirable inactivation can be
reduced by increasing the amount of dietary arginine,
demonstrating that dietary interventions can influence
drugemicrobiota interactions [21]. Only E. lenta strains
carrying the “cardiac glycoside reductase” (cgr) operon
carry out this biotransformation. The abundance of
cardiac glycoside reductase in stool samples has been
shown to predict digoxin inactivation and the resulting
reduction in drug activity [21,22]. This example clearly
demonstrates that genomic and transcriptomic analysesCurrent Opinion in Systems Biology 2017, 4:43–52of the gut microbiota can be useful for predicting drug
responses [12,16].
Additionally, gut microbes can indirectly affect the drug
response and toxicity by the production of microbial
metabolites. One example is the gut microbial produc-
tion of p-cresol that competes with acetaminophen
(paracetamol) for sulfonation by a liver enzyme and thus
contributes to drug toxicity in certain individuals [10].
To date, few mechanistic insights have been provided for
the effects of drugemicrobiota interactions, including
drug efficacy and safety, and the species capable of drug
transformations are largely unknown [17]. Moreover, the
gut microbiota is characterized by functional redun-
dancy, i.e., the same functions can be performed by
multiple bacteria that may be either closely or distantly
related [23]. This redundancy also extends to drug-
metabolizing genes in multiple species across phyla.
Hence, a microbiota-wide systematic approach to
exploiting and characterizing the capabilities of the gut
microbiota to modulate drug metabolism is urgently
required.
Computational modeling approaches
Pharmacokinetic models quantitatively describe the ab-
sorption, distribution, metabolism and elimination
(ADME) of a drug to predict the time course of a drug’s
concentration in the body [24,25]. In particular, physi-
ologically based pharmacokinetic (PBPK) models, which
compose the core of quantitative systems pharmacology
[26,27], describe whole-body drug kinetics by using or-
dinary differential equations and an organ compartment
structure [28,29] (Figure 2). These models contain
system-specific and drug-specific parameters. The
system-specific parameters include blood flow, organ
volumes, enzyme and transporter expression, and plasma
protein concentrations [30]. The drug-specific parame-
ters include intrinsic clearances, volume of distribution,
solubility and physicochemical parameters, tissue parti-
tioning, plasma protein binding affinity, and membrane
permeability [30]. The drug-dependent parameters
allow for the mechanistic extrapolation of human phar-
macokinetics from in vitro and in silico data via a
“bottom-up” approach [31]. Whole-body PBPK models
have been published for at least 50 drugs [32e34],
including 32 with an advanced compartment absorption
and transit model (ACAT). The ACAT model [35] was
based on a CAT model [36], which did not consider the
dissolution of solid particles. The ACAT model con-
siders nine gastrointestinal compartments, being the
stomach, seven small intestinal segments, and the large
intestine. It represents pH-dependent drug solubility,
controlled release, drug absorption by the stomach and
colon, metabolism in the gut or liver, degradation in the
lumen, changes in absorption surface area, changes in
drug transporter densities, and changes in effluxwww.sciencedirect.com
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permeability may continue for absorption in the colon.
PBPK models can be personalized by using system-
specific parameters [37,38]. Physiological parameters
from specific populations include specific parameters for
infants [39,40], pregnant women [41,42], and elderlyFigure 1
Top. The human gut microbiota modulates drug metabolism in a direct and in
modeling approaches for identification. Adapted from Ref. [20]. Bottom. Huma
frequently used for treating solid tumors. Approximately 35% of irinotecan-tre
festing as neutropenia and severe diarrhea, and they require unplanned dose
treatment [72]. The liver enzyme uridine-diphosphate glucuronosyltransferase
corresponding gene have been reported [72] but are unlikely to be the only fac
cleared via the enterohepatic route and may also be reabsorbed in the small
glucuronidases can reactivate irinotecan by removing glucuronate, which can
www.sciencedirect.compeople [43]. Despite the mechanistic details captured
in PBPK models, they do not account for microbial
metabolism. Moreover, they do not permit personaliza-
tion based on dietary, microbial, or genetic data. Also,
current PBPK models do not yet connect with the un-
derlying network of genes, proteins, and biochemical
reactions of human metabolism.direct manner. Particularly, the indirect mechanism relies computational
n and microbial metabolism of irinotecan, a chemotherapeutic drug that is
ated patients experience severe life-threatening toxicity, commonly mani-
reductions or the discontinuation of the therapy, thus prohibiting effective
1 (UDPGT1) catalyzes the inactivation of irinotecan. Polymorphisms in the
tor in the variability in drug toxicity. Inactivated (glucuronated) irinotecan is
intestine and excreted after passing the colon. Colonic microbial beta-
be used as a carbon source by certain microbes.
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Figure 2
Top: Schematic representation of a combined COBRA-PBPK multi-organ model. Each organ-specific model can be derived from the generic human
metabolic reconstruction (e.g., [45]) and consists of seven intra-cellular compartments (cytosol [c], nucleus, mitochondria, peroxisome, lysosome,
endoplasmatic reticulum, and the golgi apparatus). The microbial models consist of two compartments each, i.e., cytosol and extra-organismal space and
could be individualized using metagenomic data. The arterial blood compartment is illustrated with red lines, while the venous blood is represented with
blue lines. Each organ contains an exchange compartment with the respective blood compartment ([ba] and [bv]). GI tract = gastro-intestinal tract.
IEC = Intestinal epithelial cell. Bottom: Pseudoalgorithm for solving iteratively the hybrid PBPK and COBRA model. Step 0 is initialization, and steps 1–4
are iteratively repeated for a user-specified duration. Symbols: c, concentration of a drug metabolite; t, time point; vj, jth reaction from the set of reactions
U that is present in both the PBPK and the COBRA model; v, flux vector containing a reaction rate for each reaction in the COBRA; model; lb, lower flux
bound; and ub, upper flux bound.
46 Pharmacology and drug discovery (2017)
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a metabolic reconstruction of an organism is assembled
in a bottom-up manner on the basis of reaction stoi-
chiometry and physicochemical properties obtained
from genome annotations and biochemical and physio-
logical data [44]. The conversion of a metabolic recon-
struction into a condition-specific model includes the
transformation of the biochemical reaction list into a
mathematical format (a stoichiometric matrix,
S2ℝmxn). It also requires the imposition of physico-
chemical constraints (e.g., mass conservation) and
designation of reactions for exchange of mass across
systems [44]. The COBRA approach assumes that the
modeled system is in a steady state

S:v ¼ dcdth0

.
These constraints result in an underdetermined system of
linear equations that includes fewer equations (mass-
balances) than variables (reaction fluxes, v2ℝn); thus, a
polyhedral convex steady-state solution space contains
all of the feasible steady-state solutions [44]. Adding
further constraints (e.g., nutrient uptake rates, enzyme
reaction rates) to the model can restrict the solution
space to solutions that are biologically relevant under
the given condition. Despite incomplete knowledge of
many reaction rates, kinetic parameters, and metabo-
lites and enzyme concentrations, COBRA permits the
prediction of feasible phenotypic properties of the
modeled system. Comprehensive models of human
metabolism (http://vmh.life) [45e47] exist. Addition-
ally, we have created a stoichiometric reaction module,
compatible with the human metabolic reconstruction
[45] describing the metabolic transformation of the 18
most highly prescribed drugs, including statins, anti-
hypertensions, immunosuppressants, and analgesics
[48]. Such drug metabolic reactions are required to
allow for the integration of the pharmacokinetic pa-
rameters with the COBRA models (see next section).
The COBRA approach has been applied to numerous
biomedical questions, including the phenotypic conse-
quences of single nucleotide polymorphisms [49] and
enzyme deficiencies [45,50,51], and predictions of side
and off-target effects of drugs [52,53]. With these re-
sources in place, attention is now turning to their
integration.
Integration of PBPK and COBRA modeling
To overcome the limitations associated with the steady-
state assumption in COBRA models and the lack of
biochemical details of PBPK models, hybrid COBRA-
PBPK modeling approaches have been recently
explored [54e56] (Figure 2). For instance, Krauss et al.
[55] integrated a COBRA model of cellular liver meta-
bolism, which consisted of 777 metabolites and 2539
reactions [57], with a PBPK model of an human adult to
demonstrate an increase in predictive accuracy and
mechanistic understanding for allopurinol treatment,www.sciencedirect.comammonia detoxification, and paracetamol toxication. In a
subsequent study, we combined seven copies of a
COBRA model for a small intestinal epithelial cell [18],
each consisting of 433 metabolites and 1318 reactions,
with a physiology-based pharmacokinetic ACAT model
[34]. We used this model to investigate the role of in-
testinal absorption on the bioavailability of levodopa, the
predominant drug administered to patients with
Parkinson’s disease. Investigating the different model
parameters, we identified that plasma-level of levodopa
were most sensitive to the gastric emptying rate and the
loss due to microbial activity. For instance, Helicobacter
pylori, which is frequently found in the stomach, binds
levodopa and thereby reduces its bioavailability.
Accounting for microbial metabolism and dietary
information
As a next step, more organs in PBPK models need to be
represented at a molecular level. To this end, numerous
cell- and tissue-specific metabolic reconstructions have
been published [57e61]. To capture the gut microbial
metabolism, we have recently published a most
comprehensive collection of semi-manually curated
metabolic reconstructions of 773 human gut microbes
[62], named AGORA. This resource enables modeling of
gut microbial communities and their interactions with
the humanhost [63].However, thesemicrobialmetabolic
models do not yet capture xenobiotic metabolism [64],
which will require the use using context-based compar-
ative genomics techniques [65], to identify microbial
enzymes known to modify drugs. The AGORA models
can be combined into a microbiota community model
[63] and parameterized using metagenomics data. This
can be achieved by formulation of a microbial community
biomass reaction summing all of the individual microbial
biomass reaction fluxes. The stoichiometric coefficients
of this community biomass reaction canbe adapted on the
basis of the relative microbial abundance reported in
metagenomics data. The microbial community biomass
reaction can be constrained such that its rate corresponds
to the fecal excretion rate of an average human (e.g., once
every 12e24 h). Finally, the effect of diet as a modulator
of human health and microbial composition has been
studied using COBRA modeling [59,63,66,67]. One
excellent example has used themolecular composition of
24 defined food items for predicting their effect on
human and microbial metabolism [66]. However, druge
diet interactions have not yet been computationally
modeled using a COBRA modeling approach.
Development of efficient computational approaches
for hybrid COBRA-PBPK modeling
To reliably and efficiently integrate PBPK and COBRA
at large scale, using the available resources (Table1,
Figure 2), the available hybrid modeling approaches
needs to be refined. For instance, to ensure that the
changes in calculated flux vectors between twoCurrent Opinion in Systems Biology 2017, 4:43–52
Figure 3
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Table 1
List of resources and tools for building and simulating with metabolic and pharmacokinetic models.
Biochemical data
Kyoto Encyclopedia of Genes and Genomes (KEGG) http://www.genome.jp/kegg
Virtual Metabolic Human https://vmh.life
Human Metabolome Database http://www.hmdb.ca
Chemicalize by ChemAxon http://www.chemicalize.org/
Enzyme database BRENDA www.brenda-enzymes.org
Drug metabolism
DrugBank DB http://www.drugbank.ca/
Transformer http://bioinformatics.charite.de/transformer/
XmetDB http://www.xmetdb.org/
Protein
UniProt www.uniprot.org
The Human Protein Atlas www.proteinatlas.org
Human Proteome Map http://www.humanproteomemap.org
Drug information, pharmacokinetic, and pharmacogenetics
Physiological parameters database for PBPK Modeling https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=204443
Gene-drug interaction data https://cpicpgx.org/
Drug–drug information DIDB https://www.druginteractioninfo.org
Drugs@FDA https://www.accessdata.fda.gov/scripts/cder/drugsatfda
PharmGKB https://www.pharmgkb.org/index.jsp
ClinVar http://www.ncbi.nlm.nih.gov/clinvar/
Side Effect Resource (SIDER) database http://sideeffects.embl.de/
VigiAccess http://www.vigiaccess.org/
EudraVigilance http://www.adrreports.eu/en/index.html
European database of suspected adverse drug reaction reports www.adrreports.eu/
Clinical data
ClinicalTrials.gov https://clinicaltrials.gov
Clinical trial registry https://www.clinicaltrialsregister.eu/
Human Phenotype Ontology (HPO) http://compbio.charite.de/hpoweb/showterm?id=HP:0000118
Online Mendelian Inheritance in Man (OMIM) http://www.omim.org/
Dietary information
USDA food composition databases https://ndb.nal.usda.gov/ndb/
FooDB http://foodb.ca/
Microbiome data repositories
Human Microbiome Project DACC http://hmpdacc.org/resources/data_browser.php
Integrative Human Microbiome Project (iHMP) http://ihmpdcc.org/
Human Pan-Microbe Communities (HPMC) database http://www.hpmcd.org/
EBI Metagenomics https://www.ebi.ac.uk/metagenomics/
Integrated reference catalog of the human gut microbiome http://meta.genomics.cn/meta/home
Computational model repository
Virtual Metabolic Human http://vmh.life
BIGG http://bigg.ucsd.edu/
BioModels Database https://www.ebi.ac.uk/biomodels-main/
Computational modeling tools and software
COBRA toolbox https://github.com/opencobra
GastroPlus™ http://www.simulations-plus.com/software/gastroplus/
Simcyp https://www.certara.com/software/pbpk-modeling-and-simulation/
PK-Sim http://www.systems-biology.com/products/pk-sim.html
Simulation of drug–microbiota–diet interactions Thiele et al. 49consecutive time steps respond as well-behaved func-
tions (single-valued and Lipschitz continuous) of per-
turbations in the input data, the flux balance analysis
problem can be regularized to ensure that it is a strictly
convex optimization problem [68,69] by minimizing theOverview of the proposed integrated computational approach for modelin
genomic, biochemical and physiological data, drug administration, and dietar
constructions of human and gut microbial metabolism with pharmacokinetic mo
model may yield individual-specific predictions of drug metabolic pathway fluxe
together, the proposed computational pipeline enables the simulation of clinic
the effects of dietary interventions.
www.sciencedirect.comEuclidean distance between the current and next
optimal flux vector. In addition, one could mathemati-
cally reformulate the problem by adapting techniques
from discrete mechanics to pose the dynamic trajectory
of an integrated pharmacokinetic and metabolic systemg host-diet-microbe-drug interactions. Different types of data, including
y information are integrated into a model consisting of genome-scale re-
dels of drug absorption and metabolism. Such an integrated, personalized
s, end products of drug metabolism, and patients’ drug responses. Taken
al trials through patient-specific prediction of drug response, drug toxicity,
Current Opinion in Systems Biology 2017, 4:43–52
50 Pharmacology and drug discovery (2017)as the optimal solution to a variational integration
problem [70]. Moreover, a new quad-precision linear
programming solver has been recently developed to
allow for solving optimization problems ranging multiple
scales [71], e.g., due to macro e and micronutrients in
the diet. High-precision solvers are slower but guarantee
return of an optimal flux vector to 16 digits of numerical
precision, which is far beyond the precision of the bio-
logical measurements that are applied as modeling
constraints or used for the non-integer stoichiometric
coefficients (e.g., microbial abundance in the commu-
nity biomass reaction).
Pharmacokinetic simulations frequently focus on
recurrent dynamics over a finite time interval, such as a
regular 24 h-dosing regime. In this case, time can be
explicitly discretized, thus producing a set of coupled
metabolic and pharmacokinetic equations with a vari-
able for each time point. Additional constraints enforce
the dynamic continuity of each feasible trajectory. The
optimal dynamic time course can be obtained by
solving an optimization problem over this set of
possible trajectories. The key to the tractability of the
optimization problem is to couple the pharmacokinetic
model variables to linear kinetic reactions within the
metabolic model. Therefore, the rate of each drug
diffusion reaction in a metabolic model is a linear
function of the drug concentration, and with a speci-
fied diffusion coefficient, a rate variable can be linearly
coupled in a COBRA model to a concentration variable
in a discrete dynamical system. This discretized
system is high-dimensional but amenable to parallel
computing because only the constraints enforcing dy-
namic continuity share variables representing different
time points.Conclusion
Despite the importance of diet and gut microbiota in
drug metabolism, none of the current computational
modeling approaches have integrated dietemicrobiotae
drug interactions. Hybrid COBRA-PBPK modeling le-
verages their individual strengths and overcomes some
of their intrinsic weaknesses, e.g., steady-state
assumption in COBRA and limited molecular details
in PBPK modeling. Building on the growing knowledge
of the gut microbiota and using cutting-edge computa-
tional modeling approaches will enable an unprece-
dented level of mechanistic understanding of
personalized drugemicrobiotaediet interactions. This
new generation COBRA-PBPK models will combine a
multi-level in silico description of human, microbial, and
drug metabolism, which accurately represents the un-
derlying network of genes, proteins, and biochemical
reactions, as well as physiological processes and drug
pharmacokinetics. Consequently, individual physiolog-
ical parameters as well as exogenous factors that alter
drug bioavailability can be used to generate personalizedCurrent Opinion in Systems Biology 2017, 4:43–52predictive models (Figure 3). More individualized
treatment strategies, developed in silico yet based on
individualized in vivo data, have great potential to
contribute to personalized medicine and will enable in
silico clinical trials and thereby directly contribute to
the design of in vivo clinical trials, by enabling patient
stratification to reduce the heterogeneity in treatment
responses. (See Table 1)
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